Managing Diabetes — While on Targeted Therapy

No. Diabetes is a consideration in how treatment is planned and monitored, not a reason to rule targeted therapy out. Your oncologist will factor your diabetes control into the plan and may ask your diabetes specialist or endocrinologist to be involved from the start. The aim is to manage both conditions safely at the same time, not to choose between them.

mTOR inhibitors and PI3K inhibitors are the two classes most consistently associated with raised blood sugar, and NCCN and ASCO guidance for both specifically addresses glucose monitoring and management. If you are starting either of these, ask your oncologist before your first dose whether your blood glucose checking routine should change. Other targeted therapies have less consistent effects, but any new treatment is worth discussing with your diabetes team.

They may. If the treatment raises your blood sugar, your usual dose may no longer be enough to keep readings in your normal range. Some diabetes medicines may also be reviewed for suitability during cancer treatment. Any changes should come from your treating team based on your actual readings over time — do not adjust doses yourself, because a single high or low reading tells less than the pattern does.

More often than before treatment, particularly in the first weeks after starting a new targeted therapy. The right frequency depends on which treatment you are on and how stable your diabetes has been. Ask your oncology team for a specific checking schedule before your first dose rather than continuing your pre-treatment routine without reviewing it. Bring those readings to every appointment.

Report the same day if you feel unusually thirsty, need to pass urine far more than normal, have blurred vision, feel confused or very tired, or feel shaky, sweaty, or faint. Both high and low blood sugar can become dangerous quickly. Do not wait for your next scheduled appointment — call your oncology team the day symptoms appear, or go to emergency care if symptoms are sudden or severe.

Usually yes, and your oncologist will often prefer to keep it going. Metformin is well tolerated alongside most targeted therapies and remains widely used during cancer treatment. There are situations where it may be paused — around certain procedures, for example — and your team will advise you if and when that applies. Do not stop it on your own without asking first.

Your team will decide whether to adjust your diabetes medicine, pause or reduce the targeted therapy, or both. The decision depends on how far out of range your readings are, how long the problem has continued, and how well the cancer is responding to treatment. Keeping a consistent glucose log is what allows your team to see the pattern and act on it safely — without that record, the picture is incomplete.

Often yes, when the treatment was what was raising it. Raised blood sugar linked to mTOR or PI3K inhibitors typically improves once treatment ends, though the timeline varies from person to person. If your diabetes was well controlled before treatment, that level of control may return. Your diabetes medicines may then need stepping down to avoid low blood sugar readings — another reason to stay in contact with both your oncology and diabetes teams as treatment finishes.